HTG Molecular Diagnostics, Inc. (HTGM) Issues Quarterly Earnings Results, Meets Estimates
HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) issued its quarterly earnings data on Tuesday. The medical research company reported ($0.60) earnings per share for the quarter, meeting the consensus estimate of ($0.60), Morningstar.com reports. The firm had revenue of $1.76 million for the quarter, compared to analyst estimates of $1.80 million. HTG Molecular Diagnostics had a negative net margin of 440.31% and a negative return on equity of 1,538.49%.
HTG Molecular Diagnostics (NASDAQ HTGM) traded down 2.17% during trading on Wednesday, hitting $2.25. 465,377 shares of the stock were exchanged. HTG Molecular Diagnostics has a 1-year low of $1.20 and a 1-year high of $13.25. The stock’s market cap is $21.43 million. The firm’s 50 day moving average price is $2.50 and its 200-day moving average price is $3.35.
ILLEGAL ACTIVITY WARNING: This piece of content was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another website, it was stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.watchlistnews.com/htg-molecular-diagnostics-inc-htgm-issues-quarterly-earnings-results-meets-estimates/1466380.html.
HTGM has been the topic of several recent research reports. HC Wainwright set a $6.00 price objective on shares of HTG Molecular Diagnostics and gave the company a “buy” rating in a research report on Wednesday. Rodman & Renshaw raised their price objective on shares of HTG Molecular Diagnostics from $4.50 to $6.00 and gave the company a “buy” rating in a research report on Tuesday, May 16th. Zacks Investment Research raised shares of HTG Molecular Diagnostics from a “hold” rating to a “buy” rating and set a $4.50 price objective on the stock in a research report on Thursday, May 11th. Canaccord Genuity raised their price objective on shares of HTG Molecular Diagnostics from $5.50 to $6.50 and gave the company a “hold” rating in a research report on Wednesday, April 19th. Finally, ValuEngine raised shares of HTG Molecular Diagnostics from a “strong sell” rating to a “sell” rating in a research report on Monday, July 17th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $5.75.
HTG Molecular Diagnostics Company Profile
HTG Molecular Diagnostics, Inc is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development.
Receive News & Ratings for HTG Molecular Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.